NO312996B1 - Hormonell, östroprogestativ trisekvensiell kombinasjon og fremgangsmåte for fremstilling av en slik - Google Patents

Hormonell, östroprogestativ trisekvensiell kombinasjon og fremgangsmåte for fremstilling av en slik Download PDF

Info

Publication number: NO312996B1
Authority: NO; Norway
Prior art keywords: estradiol; hormonal; dose; estroprogestative; combination according
Prior art date: 1995-08-01

Application number

NO19971449A

Other languages

English (en)

Norwegian (no)

Other versions

NO971449D0 (no

NO971449L (no

Inventor

Michel Lanquetin

Jacques Paris

Jean-Louis Thomas

Original Assignee

Theramex

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-08-01

Filing date

1997-03-26

Publication date

2002-07-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9481610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO312996(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-03-26 Application filed by Theramex filed Critical Theramex

1997-03-26 Publication of NO971449D0 publication Critical patent/NO971449D0/no

1997-05-30 Publication of NO971449L publication Critical patent/NO971449L/no

2002-07-29 Publication of NO312996B1 publication Critical patent/NO312996B1/no

Links

230000003054 hormonal effect Effects 0.000 title claims description 11
238000000034 method Methods 0.000 title claims description 8
239000007983 Tris buffer Substances 0.000 title 1
229960005309 estradiol Drugs 0.000 claims description 45
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 23
229930182833 estradiol Natural products 0.000 claims description 21
229960004190 nomegestrol acetate Drugs 0.000 claims description 19
IIVBFTNIGYRNQY-YQLZSBIMSA-N nomegestrol acetate Chemical group C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 IIVBFTNIGYRNQY-YQLZSBIMSA-N 0.000 claims description 19
239000000203 mixture Substances 0.000 claims description 12
238000002360 preparation method Methods 0.000 claims description 10
239000000583 progesterone congener Substances 0.000 claims description 10
239000000262 estrogen Substances 0.000 claims description 9
229940011871 estrogen Drugs 0.000 claims description 8
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
239000008119 colloidal silica Substances 0.000 claims description 4
239000008101 lactose Substances 0.000 claims description 4
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
239000008108 microcrystalline cellulose Substances 0.000 claims description 4
229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
230000001076 estrogenic effect Effects 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
ZVVGLAMWAQMPDR-WVEWYJOQSA-N (8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol;hydrate Chemical compound O.OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 ZVVGLAMWAQMPDR-WVEWYJOQSA-N 0.000 claims description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
239000003086 colorant Substances 0.000 claims description 2
238000001035 drying Methods 0.000 claims description 2
239000000975 dye Substances 0.000 claims description 2
229960003851 estradiol hemihydrate Drugs 0.000 claims description 2
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 2
229940046813 glyceryl palmitostearate Drugs 0.000 claims description 2
238000005469 granulation Methods 0.000 claims description 2
230000003179 granulation Effects 0.000 claims description 2
239000008024 pharmaceutical diluent Substances 0.000 claims description 2
239000008213 purified water Substances 0.000 claims description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
230000021615 conjugation Effects 0.000 claims 5
150000002148 esters Chemical class 0.000 claims 5
UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 claims 1
229940068196 placebo Drugs 0.000 description 31
239000000902 placebo Substances 0.000 description 31
238000011282 treatment Methods 0.000 description 13
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
206010060800 Hot flush Diseases 0.000 description 9
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
208000033830 Hot Flashes Diseases 0.000 description 7
230000009245 menopause Effects 0.000 description 7
229940109239 creatinine Drugs 0.000 description 6
206010006298 Breast pain Diseases 0.000 description 5
208000006662 Mastodynia Diseases 0.000 description 5
210000004696 endometrium Anatomy 0.000 description 5
208000032843 Hemorrhage Diseases 0.000 description 4
208000002193 Pain Diseases 0.000 description 4
206010046788 Uterine haemorrhage Diseases 0.000 description 4
230000004872 arterial blood pressure Effects 0.000 description 4
230000000740 bleeding effect Effects 0.000 description 4
210000000481 breast Anatomy 0.000 description 4
235000012000 cholesterol Nutrition 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000002559 palpation Methods 0.000 description 4
102000002260 Alkaline Phosphatase Human genes 0.000 description 3
108020004774 Alkaline Phosphatase Proteins 0.000 description 3
108010071619 Apolipoproteins Proteins 0.000 description 3
102000007592 Apolipoproteins Human genes 0.000 description 3
206010049816 Muscle tightness Diseases 0.000 description 3
LCYXYLLJXMAEMT-SAXRGWBVSA-N Pyridinoline Chemical compound OC(=O)[C@@H](N)CCC1=C[N+](C[C@H](O)CC[C@H](N)C([O-])=O)=CC(O)=C1C[C@H](N)C(O)=O LCYXYLLJXMAEMT-SAXRGWBVSA-N 0.000 description 3
230000003187 abdominal effect Effects 0.000 description 3
230000007423 decrease Effects 0.000 description 3
238000011835 investigation Methods 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
102000004411 Antithrombin III Human genes 0.000 description 2
108090000935 Antithrombin III Proteins 0.000 description 2
108010039209 Blood Coagulation Factors Proteins 0.000 description 2
102000015081 Blood Coagulation Factors Human genes 0.000 description 2
108010049003 Fibrinogen Proteins 0.000 description 2
102000008946 Fibrinogen Human genes 0.000 description 2
206010030247 Oestrogen deficiency Diseases 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
229960005348 antithrombin iii Drugs 0.000 description 2
239000003114 blood coagulation factor Substances 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
230000010072 bone remodeling Effects 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
238000012937 correction Methods 0.000 description 2
230000004882 diastolic arterial blood pressure Effects 0.000 description 2
230000002357 endometrial effect Effects 0.000 description 2
229940012952 fibrinogen Drugs 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
230000005906 menstruation Effects 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
230000004873 systolic arterial blood pressure Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
102000005666 Apolipoprotein A-I Human genes 0.000 description 1
108010059886 Apolipoprotein A-I Proteins 0.000 description 1
102000018619 Apolipoproteins A Human genes 0.000 description 1
108010027004 Apolipoproteins A Proteins 0.000 description 1
102000018616 Apolipoproteins B Human genes 0.000 description 1
108010027006 Apolipoproteins B Proteins 0.000 description 1
206010003439 Artificial menopause Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
108010028554 LDL Cholesterol Proteins 0.000 description 1
238000008214 LDL Cholesterol Methods 0.000 description 1
206010027514 Metrorrhagia Diseases 0.000 description 1
102000004067 Osteocalcin Human genes 0.000 description 1
108090000573 Osteocalcin Proteins 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
102000013566 Plasminogen Human genes 0.000 description 1
108010051456 Plasminogen Proteins 0.000 description 1
101800004937 Protein C Proteins 0.000 description 1
102000017975 Protein C Human genes 0.000 description 1
229940096437 Protein S Drugs 0.000 description 1
102000029301 Protein S Human genes 0.000 description 1
108010066124 Protein S Proteins 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
101800001700 Saposin-D Proteins 0.000 description 1
RUJWZZRJSQGFCW-OGPYDZPMSA-N [(8s,9s,10r,13s,14s,17r)-17-acetyl-6,13-dimethyl-3-oxo-1,2,8,9,10,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RUJWZZRJSQGFCW-OGPYDZPMSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000000923 atherogenic effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
201000006828 endometrial hyperplasia Diseases 0.000 description 1
229960003575 estradiol acetate Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000003163 gonadal steroid hormone Substances 0.000 description 1
102000036124 hormone binding proteins Human genes 0.000 description 1
108091011044 hormone binding proteins Proteins 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
238000005470 impregnation Methods 0.000 description 1
230000000938 luteal effect Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
-1 natural estrogen Chemical compound 0.000 description 1
230000000422 nocturnal effect Effects 0.000 description 1
230000027758 ovulation cycle Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
229960000856 protein c Drugs 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000009291 secondary effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO19971449A 1995-08-01 1997-03-26 Hormonell, östroprogestativ trisekvensiell kombinasjon og fremgangsmåte for fremstilling av en slik NO312996B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9509364A FR2737411B1 (fr)	1995-08-01	1995-08-01	Nouveaux medicaments hormonaux et leur utilisation pour la correction des carences estrogeniques
PCT/IB1996/000754 WO1997004784A1 (fr)	1995-08-01	1996-07-29	Nouveaux medicaments hormonaux et leur utilisation pour la correction des carences estrogeniques

Publications (3)

Publication Number	Publication Date
NO971449D0 NO971449D0 (no)	1997-03-26
NO971449L NO971449L (no)	1997-05-30
NO312996B1 true NO312996B1 (no)	2002-07-29

Family

ID=9481610

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19971449A NO312996B1 (no)	1995-08-01	1997-03-26	Hormonell, östroprogestativ trisekvensiell kombinasjon og fremgangsmåte for fremstilling av en slik

Country Status (30)

Country	Link
US (1)	US5891867A (cs)
EP (1)	EP0783310B1 (cs)
JP (1)	JPH10507207A (cs)
KR (1)	KR100450649B1 (cs)
CN (1)	CN1138547C (cs)
AP (1)	AP829A (cs)
AR (1)	AR004502A1 (cs)
AT (1)	ATE225659T1 (cs)
AU (1)	AU722355B2 (cs)
BR (1)	BR9606549A (cs)
CA (1)	CA2201368C (cs)
CZ (1)	CZ289706B6 (cs)
DE (1)	DE69624214T2 (cs)
DK (1)	DK0783310T3 (cs)
DZ (1)	DZ2078A1 (cs)
ES (1)	ES2184880T3 (cs)
FR (1)	FR2737411B1 (cs)
HU (1)	HU229843B1 (cs)
IL (1)	IL120558A (cs)
MA (1)	MA23946A1 (cs)
MX (1)	MX9702381A (cs)
MY (1)	MY117307A (cs)
NO (1)	NO312996B1 (cs)
OA (1)	OA10411A (cs)
PT (1)	PT783310E (cs)
RU (1)	RU2188641C2 (cs)
TN (1)	TNSN96101A1 (cs)
TW (1)	TW473390B (cs)
WO (1)	WO1997004784A1 (cs)
ZA (1)	ZA966545B (cs)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2754179B1 (fr) *	1996-10-08	1998-12-24	Theramex	Nouvelle composition hormononale et son utilisation
WO2001030355A1 (fr) *	1999-10-25	2001-05-03	Laboratoire Theramex	Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
US6787531B1 (en) *	1999-08-31	2004-09-07	Schering Ag	Pharmaceutical composition for use as a contraceptive
WO2001030356A1 (fr) *	1999-10-25	2001-05-03	Laboratoire Theramex	Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
US20020132801A1 (en) *	2001-01-11	2002-09-19	Schering Aktiengesellschaft	Drospirenone for hormone replacement therapy
FR2814074B1 (fr) *	2000-09-15	2003-03-07	Theramex	Nouvelles compositions estro-progestatives topiques a effet systemique
US20020151732A1 (en) *	2001-01-05	2002-10-17	Claes Ohlsson	Estrogen receptors
EP1390038A2 (en)	2001-05-16	2004-02-25	Endeavor Pharmaceuticals	Treatment of conditions relating to hormone deficiencies by administration of progestins
NZ591627A (en) *	2001-12-05	2012-09-28	Teva Womens Health Inc	Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US7008979B2 (en) *	2002-04-30	2006-03-07	Hydromer, Inc.	Coating composition for multiple hydrophilic applications
CA2771944A1 (en) *	2003-07-16	2005-01-27	Teva Women's Health, Inc.	Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
US20070111975A1 (en) *	2004-10-07	2007-05-17	Duramed Pharmaceuticals, Inc.	Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US8022053B2 (en) *	2004-11-02	2011-09-20	Bayer Schering Pharma Aktiengesellschaft	Oral solid dosage forms containing a low dose of estradiol
AR065816A1 (es) *	2007-03-26	2009-07-01	Theramex	Regimen anticonceptivo oral

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4390531A (en) *	1981-08-10	1983-06-28	Syntex Pharmaceuticals International Ltd.	Method of contraception using peak progestogen dosage
US4826831A (en) *	1983-08-05	1989-05-02	Pre Jay Holdings Limited	Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
US4870066A (en) *	1986-08-11	1989-09-26	The University Of Kentucky Research Foundation	Method and composition for safely delaying parturition and synchronizing farrowing in swine
EP0483077B1 (en) *	1990-09-28	1995-12-06	I.F.L.O. S.a.s. di Giorgio e Aldo Laguzzi	A method for carrying out the synthesis of a contraceptive and menstrual cycle controlling drug having oncostatic, antikinetosic, preventive and therapeutic properties for treatment of mammary tumours and melanomas.
FR2695826B1 (fr) *	1992-09-21	1995-01-06	Theramex	Nouvelles compositions pharmaceutiques à base de dérivés de nomégestrol et leurs procédés d'obtention.

1995
- 1995-08-01 FR FR9509364A patent/FR2737411B1/fr not_active Expired - Fee Related
1996
- 1996-07-22 MA MA24321A patent/MA23946A1/fr unknown
- 1996-07-26 MY MYPI96003099A patent/MY117307A/en unknown
- 1996-07-29 JP JP9507406A patent/JPH10507207A/ja not_active Ceased
- 1996-07-29 DK DK96923018T patent/DK0783310T3/da active
- 1996-07-29 HU HU9900612A patent/HU229843B1/hu unknown
- 1996-07-29 AP APAP/P/1997/000979A patent/AP829A/en active
- 1996-07-29 DE DE69624214T patent/DE69624214T2/de not_active Expired - Lifetime
- 1996-07-29 MX MX9702381A patent/MX9702381A/es active IP Right Grant
- 1996-07-29 CZ CZ1997967A patent/CZ289706B6/cs not_active IP Right Cessation
- 1996-07-29 US US08/817,329 patent/US5891867A/en not_active Expired - Lifetime
- 1996-07-29 EP EP96923018A patent/EP0783310B1/fr not_active Expired - Lifetime
- 1996-07-29 CA CA2201368A patent/CA2201368C/fr not_active Expired - Lifetime
- 1996-07-29 AT AT96923018T patent/ATE225659T1/de active
- 1996-07-29 AU AU63674/96A patent/AU722355B2/en not_active Expired
- 1996-07-29 PT PT96923018T patent/PT783310E/pt unknown
- 1996-07-29 CN CNB96191100XA patent/CN1138547C/zh not_active Expired - Lifetime
- 1996-07-29 KR KR1019970702125A patent/KR100450649B1/ko not_active Expired - Lifetime
- 1996-07-29 IL IL12055896A patent/IL120558A/en not_active IP Right Cessation
- 1996-07-29 RU RU97108279/14A patent/RU2188641C2/ru active
- 1996-07-29 ES ES96923018T patent/ES2184880T3/es not_active Expired - Lifetime
- 1996-07-29 BR BR9606549A patent/BR9606549A/pt not_active Application Discontinuation
- 1996-07-29 WO PCT/IB1996/000754 patent/WO1997004784A1/fr not_active Ceased
- 1996-07-30 DZ DZ960122A patent/DZ2078A1/fr active
- 1996-07-31 AR ARP960103818A patent/AR004502A1/es not_active Application Discontinuation
- 1996-08-01 TN TNTNSN96101A patent/TNSN96101A1/fr unknown
- 1996-08-01 ZA ZA966545A patent/ZA966545B/xx unknown
- 1996-09-24 TW TW085111673A patent/TW473390B/zh not_active IP Right Cessation
1997
- 1997-03-26 NO NO19971449A patent/NO312996B1/no not_active IP Right Cessation
- 1997-04-01 OA OA60985A patent/OA10411A/fr unknown

Also Published As

Publication number	Publication date
PT783310E (pt)	2003-02-28
ATE225659T1 (de)	2002-10-15
CZ96797A3 (cs)	1998-08-12
ZA966545B (en)	1997-05-08
NO971449D0 (no)	1997-03-26
MY117307A (en)	2004-06-30
AU722355B2 (en)	2000-07-27
HUP9900612A3 (en)	1999-11-29
DE69624214D1 (de)	2002-11-14
TNSN96101A1 (fr)	2005-03-15
ES2184880T3 (es)	2003-04-16
IL120558A0 (en)	1997-07-13
IL120558A (en)	2002-09-12
CZ289706B6 (cs)	2002-03-13
EP0783310A1 (fr)	1997-07-16
OA10411A (fr)	2001-12-06
AP829A (en)	2000-05-03
FR2737411B1 (fr)	1997-10-17
DE69624214T2 (de)	2003-07-10
HUP9900612A2 (hu)	1999-07-28
AR004502A1 (es)	1998-12-16
AU6367496A (en)	1997-02-26
KR970706004A (ko)	1997-11-03
HU229843B1 (en)	2014-09-29
DK0783310T3 (da)	2003-02-10
CA2201368C (fr)	2010-12-07
DZ2078A1 (fr)	2002-10-22
WO1997004784A1 (fr)	1997-02-13
MX9702381A (es)	1998-02-28
CN1167438A (zh)	1997-12-10
MA23946A1 (fr)	1997-04-01
NO971449L (no)	1997-05-30
JPH10507207A (ja)	1998-07-14
CA2201368A1 (fr)	1997-02-13
BR9606549A (pt)	1998-06-23
HK1005227A1 (en)	1998-12-31
RU2188641C2 (ru)	2002-09-10
TW473390B (en)	2002-01-21
FR2737411A1 (fr)	1997-02-07
AP9700979A0 (en)	1997-07-31
KR100450649B1 (ko)	2004-11-16
US5891867A (en)	1999-04-06
EP0783310B1 (fr)	2002-10-09
CN1138547C (zh)	2004-02-18

Legal Events

Date	Code	Title	Description
2016-08-08	MK1K	Patent expired

Publication	Publication Date	Title
Christensen et al.	1982	Dose-response evaluation of cyclic estrogen/gestagen in postmenopausal women: placebo-controlled trial of its gynecologic and metabolic actions
Sitruk-Ware et al.	1987	Oral micronized progesterone: Bioavailability pharmacokinetics, pharmacological and therapeutic implications—A review
KR100365879B1 (ko)	2003-03-10	프로게스테론길항제및게스타겐을포함하는자궁내막증식증또는자궁평활근종치료제
DE69729956T2 (de)	2004-12-16	Orale einstufige empfängnisverhütungsmethode und kombinationspräparat das gestagen und estrogen enthält
US20050220900A1 (en)	2005-10-06	Use of extracts containing phytoestrogen selectively modulating estrogen-receptor-beta
US5891867A (en)	1999-04-06	Hormonal medicaments and their use for the correction of oestrogenic deficiencies
JPH09502194A (ja)	1997-03-04	少なくとも１種のプロゲストーゲンおよび少なくとも１種のエストロゲンを含む、代替療法用製剤
KR100782638B1 (ko)	2007-12-06	에스트로겐 화합물 및 프로게스테론 화합물로 이루어진호르몬 조성물
Voedisch et al.	2021	Oestrogen component of COCs: have we finally found a replacement for ethinyl estradiol?
Hassager et al.	1988	Blood pressure during oestrogen/progestogen substitution therapy in healthy post-menopausal women
Reginster et al.	1993	Effect of transdermal l7β-estradiol and oral conjugated equine estrogens on biochemical parameters of bone resorption in natural menopause
JENSEN et al.	1987	Cyproterone acetate, an alternative progestogen in postmenopausal hormone replacement therapy? Effects on serum lipids and lipoproteins
CA2623024C (en)	2012-03-06	Use of estradiol valerate or estradiol combined with dienogest for the oral therapy of dysfunctional uterine bleeding in the form of oral contraceptives
CZ301982B6 (cs)	2010-08-25	Antikoncepcní kompozice obsahující estradiol nebo jeho ester a nomegestrolacetát
US20060183725A1 (en)	2006-08-17	Pharmaceutical preparation for oral contraception
CA2590004A1 (en)	2006-08-24	Contraceptive pharmaceutical preparation
Cohen	2003	Anti-osteoporotic medications: traditional and nontraditional
Christiansen	2019	in hormone replacement therapy
AU640112B2 (en)	1993-08-19	Estrogen and progestogen containing oral dosage forms
JPH08508502A (ja)	1996-09-10	骨粗しょう症の治療方法および治療用組成物
RU2201233C1 (ru)	2003-03-27	Способ профилактики хронических циститов в период менопаузы
KR19980703058A (ko)	1998-09-05	폐경기 중 및 폐경기 전 여성을 위한 호르몬 대체 치료 및데포 피임제로서 유용한 월 1회 주사제
Rolland	1982	Concluding Summary
HK1044486A1 (zh)	2002-10-25	使用性激素来获得可用於治疗不合需要的子宫出血的鼻腔药物组合物
MXPA01008772A (en)	2002-05-09	Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding